DMVT -505 (tapi[INVESTIGATOR_191752])  IND 104601  
Dermavant Sciences , Inc.  Clinical Study  Protocol  
Confidential  Page | 1  
 
Protocol Title:   
A Phase 4, open -label study to investigate the efficacy and safety of VTAMA® (tapi[INVESTIGATOR_191752]) cream, 1% in the 
treatment of plaque psoriasis occurring in the head and neck region  
Protocol Number:   DMVT -505-[ADDRESS_1090055]:   VTAMA (tapi[INVESTIGATOR_191752]) cream, 1%  
Brief Title:   
A study to investigate efficacy and safety of VTAMA® (tapi[INVESTIGATOR_191752]) cream, 1%  in plaque psoriasis  in the head 
and neck region   
Study Phase:   4 
Sponsor Name:  [CONTACT_790895], Inc.  
Legal Registered Address:   [ADDRESS_1090056], Morrisville, NC, [LOCATION_003]  [ZIP_CODE]  
Regulatory Agency Identifier Number(s):   IND 104601  
Approval Date:  01 Nov 2022  
  

DMVT -505 (tapi[INVESTIGATOR_191752])  IND 104601  
Dermavant Sciences , Inc.  Clinical Study  Protocol  
Confidential  Page | 2 eSignature [CONTACT_125642]  
 01 Nov 2022  
 
 Date Signed:  
This protocol  has been approved by a representative of Dermavant Sciences, Inc.  This electronic signature [CONTACT_790896].  
 
Medical Monitoring  
Medical Monitor contac t information can be found in the Study Reference Manual . 
Serious Adverse Event (SAE)/Pregnancy should be reported to the North American Safety Mailbox:  
 
 
Study Sponsor  
This study is sponsor ed by [CONTACT_280003], Inc.  
Sponsor Registered Address and Regulatory Contact  
[CONTACT_280003], Inc.  
[ADDRESS_1090057]  
Morrisville, NC  [ZIP_CODE]  
[LOCATION_003]  
  

DMVT -505 (tapi[INVESTIGATOR_191752])  IND 104601  
Dermavant Sciences , Inc.  Clinical Study  Protocol  
Confidential  Page | 3 Table of Contents   
1 Protocol Summary  ................................ ................................ ................................ ........................  8 
1.1 Synopsis  ................................ ................................ ................................ ................................ ........  8 
1.2 Schema  ................................ ................................ ................................ ................................ ..........  12 
1.3 Schedule of Ac tivities  ................................ ................................ ................................ ...................  13 
2 Introduction  ................................ ................................ ................................ ................................ ... 15 
2.1 Study Rationale  ................................ ................................ ................................ .............................  15 
2.2 Background  ................................ ................................ ................................ ................................ ... 15 
2.3 Benefit/Risk Assessment  ................................ ................................ ................................ ..............  15 
2.3.1  Risk Assessment  ................................ ................................ ................................ ...........................  16 
2.3.2  Benefit Assessment  ................................ ................................ ................................ .......................  16 
2.3.3  Overall Benefit Risk Conclusion  ................................ ................................ ................................ .. 16 
3 Objectives and Endpoints  ................................ ................................ ................................ .............  17 
4 Study Design  ................................ ................................ ................................ ................................ . 18 
4.1 Overall Design  ................................ ................................ ................................ ..............................  18 
4.2 Scient ific Rationale for Study Design  ................................ ................................ ..........................  18 
4.3 Justification for Dose  ................................ ................................ ................................ ....................  18 
4.4 End-of-Study Definition  ................................ ................................ ................................ ...............  18 
5 Study Population  ................................ ................................ ................................ ...........................  19 
5.1 Inclusion Criteria  ................................ ................................ ................................ ..........................  19 
5.2 Exclusion Criteria  ................................ ................................ ................................ .........................  20 
5.3 Lifestyle Considerations  ................................ ................................ ................................ ...............  21 
5.4 Screen Failures  ................................ ................................ ................................ ..............................  21 
5.5 Criteria for Temporarily Delaying Enrollment  ................................ ................................ .............  21 
6 Study Intervention(s) and Concomitant Therapy  ................................ ................................ .........  22 
6.1 Study Intervention(s) Administered  ................................ ................................ .............................  22 
6.2 Preparation, Handling, Storage, and Accountability  ................................ ................................ .... 22 
6.3 Assignment to Study Intervention  ................................ ................................ ................................  23 
6.4 Blinding  ................................ ................................ ................................ ................................ ........  23 
6.5 Study Interv ention Compliance  ................................ ................................ ................................ .... 23 
6.6 Dose Modification  ................................ ................................ ................................ ........................  23 
6.7 Continued Access to Study Intervention after the End of the Study  ................................ ............  23 
6.8 Treatment of Overdose  ................................ ................................ ................................ .................  23 
6.9 Prior and Concomitant Therapy  ................................ ................................ ................................ .... 24 
7 Discontinuation of Study Intervention and Participant Discontinuation/Withdrawal  ..................  25 
DMVT -505 (tapi[INVESTIGATOR_191752])  IND 104601  
Dermavant Sciences , Inc.  Clinical Study  Protocol  
Confidential  Page | 4 7.1 Discontinuation of Study Intervention ................................ ................................ ..........................  25 
7.1.1  Temporary Interruption  ................................ ................................ ................................ ................  25 
7.1.2  Rechallenge  ................................ ................................ ................................ ................................ ... 25 
7.2 Participant Discontinuation/Withdrawal from the Study  ................................ .............................  [ADDRESS_1090058] to Follow up  ................................ ................................ ................................ ..........................  25 
8 Study Assessments and Procedures  ................................ ................................ ..............................  27 
8.1 Administrative and Baseline Procedures  ................................ ................................ ......................  27 
8.1.1  Informed Consent  ................................ ................................ ................................ .........................  27 
8.1.2  Demographics  ................................ ................................ ................................ ...............................  27 
8.1.3  Medical History  ................................ ................................ ................................ ............................  27 
8.1.4  Instructions for Dosing Regimen  ................................ ................................ ................................ .. 27 
8.2 Efficacy Assessments  ................................ ................................ ................................ ...................  28 
8.2.1  Efficacy Assessments Completed by [CONTACT_10670]  ................................ ................................ ........  28 
[IP_ADDRESS]  Physician Global Assessment of Target Lesion  ................................ ................................ ...........  28 
  29 
 ... 29 
  
  
  
  
8.3 Safety Assessments  ................................ ................................ ................................ .......................  29 
8.3.1  Pregnancy Testing  ................................ ................................ ................................ ........................  30 
  
8.4 Adverse Events, Serious Adverse Events, and Other Safety Reporting  ................................ ....... 30 
8.4.1  Time Period and Frequency for Collecting AE and SAE Information  ................................ .........  30 
8.4.2  Method of Detecting AEs and SAEs  ................................ ................................ ............................  30 
8.4.3  Follow -up of AEs and SAEs  ................................ ................................ ................................ .........  31 
8.4.4  Regulatory Reporting Requirements for SAEs  ................................ ................................ .............  31 
8.4.5  Pregnancy  ................................ ................................ ................................ ................................ ..... 31 
8.5 Pharmaco kinetics  ................................ ................................ ................................ ..........................  31 
8.6 Pharmacodynamics  ................................ ................................ ................................ .......................  32 
8.7 Genetics  ................................ ................................ ................................ ................................ ........  32 
8.8 Biomarkers  ................................ ................................ ................................ ................................ .... 32 
8.9 Immunogenicity Assessments  ................................ ................................ ................................ ...... 32 
8.10  Health Economics  ................................ ................................ ................................ .........................  32 

DMVT -505 (tapi[INVESTIGATOR_191752])  IND 104601  
Dermavant Sciences , Inc.  Clinical Study  Protocol  
Confidential  Page | 5 9 Statistical Considerations  ................................ ................................ ................................ ..............  33 
9.1 Statistical Hypothesis  ................................ ................................ ................................ ....................  33 
9.1.1  Multiplicity Adjustment ................................ ................................ ................................ ................  33 
9.2 Analysis Sets  ................................ ................................ ................................ ................................ . 33 
9.3 Statistical Analyses  ................................ ................................ ................................ .......................  33 
9.3.1  General Considerations  ................................ ................................ ................................ .................  33 
9.3.2  Primary Endpoint Analysis  ................................ ................................ ................................ ...........  33 
9.3.3  Secondary Endpoint Analysis  ................................ ................................ ................................ ....... 33 
9.3.4  Exploratory Endpoint(s) Analysis  ................................ ................................ ................................  33 
9.3.5  Safety Analyses  ................................ ................................ ................................ ............................  34 
9.4 Interim Analysis  ................................ ................................ ................................ ............................  34 
9.5 Samp le Size Determination  ................................ ................................ ................................ ..........  34 
10 Supporting Documentation and Operational Considerations  ................................ .......................  35 
10.1  Appendix 1:  Regulatory, Ethical, and Study Oversight Considerations  ................................ ..... 35 
10.1.1  Regulatory and Ethical Considerations  ................................ ................................ ........................  35 
10.1.2  Financial Disclosure  ................................ ................................ ................................ .....................  35 
10.1.3  Informed Consent Process  ................................ ................................ ................................ ............  35 
10.1.4  Data Protection  ................................ ................................ ................................ .............................  36 
10.1.5  Dissemination of Clinical Study Data  ................................ ................................ ..........................  36 
10.1.6  Data Quality Assurance  ................................ ................................ ................................ ................  36 
10.1.7  Source Documents  ................................ ................................ ................................ ........................  37 
10.1.8  Study and Site Start and Closure  ................................ ................................ ................................ .. 37 
10.1.9  Publication Policy  ................................ ................................ ................................ .........................  38 
10.2  Appendix 2:  Clinical Laboratory Tests  ................................ ................................ ........................  39 
10.3  Appendix 3:  AEs and SAEs:  Definitions and Procedures for Recording, Evaluating, 
Follow -up, and Reporting  ................................ ................................ ................................ .............  40 
10.3.1  Definition of AE  ................................ ................................ ................................ ...........................  40 
10.3.2  Definition of SAE  ................................ ................................ ................................ .........................  41 
10.3.3  Recording and Follow -Up of AE and/or SAE  ................................ ................................ ..............  42 
10.3.4  Reporting of SAEs  ................................ ................................ ................................ ........................  43 
  
10.4  Appendix 4:  Contraceptive and Barrier Guidance  ................................ ................................ ....... 45 
10.4.1  Definitions  ................................ ................................ ................................ ................................ .... 45 
10.4.2  Contraception Guidance  ................................ ................................ ................................ ...............  47 
10.5  Appendix 5:  Physician Global Assessment of Target Lesion  ................................ .....................  48 

DMVT -505 (tapi[INVESTIGATOR_191752])  IND 104601  
Dermavant Sciences , Inc.  Clinical Study  Protocol  
Confidential  Page | [ADDRESS_1090059] of Tables  
Table  1: Study Intervention(s) Administered  ................................ ................................ .............................  22 
Table  2: Study Arm(s)  ................................ ................................ ................................ ................................  22 
Table  3: Fitzpatrick Skin Type Scale  ................................ ................................ ................................ ..........  27 
Table  4: Criteria for Determining the Grade/Severity of Adverse Event Terms Not Specified by [CONTACT_222185]  ................................ ................................ ................................  42 
 
  

DMVT -505 (tapi[INVESTIGATOR_191752])  IND 104601  
Dermavant Sciences , Inc.  Clinical Study  Protocol  
Confidential  Page | [ADDRESS_1090060] of Abbreviations  
Term  Description  
AE adverse event  
BSA  body surface area  
CFR  Code of Federal Regulations  
CONSORT  Consolidated Standards of Reporting Trials  
COVID -19 coronavirus disease 2019  
CTCAE  Common Terminology Criteria for Adverse Events  
CV cardiovascular  
  
eCRF  electronic case report form  
CRF  case report form  
EDC  electronic data capture  
FDA  Food and Drug Administration  
FSH follicle -stimulating hormone  
GCP  Good Clinical Practice  
HRT  hormonal replacement therapy  
IB Investigator ’s brochure  
ICF informed consent form  
ICH International Council for Harmonisation  
IEC independent ethics committee  
IND Investigational New Drug application  
IRB institutional review board  
ITT intent -to-treat 
IU international units  
  
OC observed case  
  
PGA  Physician Global Assessment  
  
PSO psoriasis  
QD once da ily 
SAE  serious adverse event  
SoA schedule of activities  
SD standard deviation  
S[LOCATION_003]R  suspected unexpected serious adverse reaction  
TEAE  treatment -emergent adverse event  
[LOCATION_003]  [LOCATION_002] of America  
USPI  [INVESTIGATOR_790845] -505 (tapi[INVESTIGATOR_191752])  IND 104601  
Dermavant Sciences , Inc.  Clinical Study  Protocol  
Confidential  Page | 8 1 Protocol Summary   
1.1 Synopsis   
Protocol Title:   A Phase 4, open -label study to investigate the efficacy  and safety of VTAMA® (tapi[INVESTIGATOR_191752]) 
cream, 1% in the treatment of plaque psoriasis occurring in the head and neck region  
Brief Title:   A study to investigate efficacy and safety of VTAMA® (tapi[INVESTIGATOR_191752]) cream, 1% in plaque 
psoriasis in the head and neck region  
Regulatory Agency Identifier Number(s):   
IND 104601  
Rationale:   
Plaque PSO in the head and neck region occurs commonly and is often underdiagnosed ( Merola  2016).  Scalp 
involvement occurs in 45 % to 56% of individuals with PSO and facial PSO typi[INVESTIGATOR_790846] a younger 
age and is estimated to affect nearly 50% of patients with PSO (Bagel  2018 ; Merola  2018).  The majority of 
patients with facial PSO also have scalp involvement ( Dopytalska  2018).  Scalp PSO can cause patients to 
feel embarrassed and self -conscious.  Facial PSO can be even more devastating  because  it cannot be hidden 
with clothing.  Despi[INVESTIGATOR_790847], disease in this area can result in considerable 
psychosocial challenges  that are not captured by [CONTACT_790867].   
Topi[INVESTIGATOR_790848]; however, due to the 
safety profile their use is limited to only short -term therapy.  Other topi[INVESTIGATOR_790849] D 
analogs offer better safety profiles, but with moderate efficacy.  The use of any topi[INVESTIGATOR_790850] ( Mosca 2021 ).  
Because  many commonly use d topi[INVESTIGATOR_790851], lack of adherence is an issue that compounds the lack of efficacy and 
poor safety profiles associated with these therapi[INVESTIGATOR_014].  Systemic  treatment, such as biologics and oral therapy, is 
reserved for the more severe and resistant cases due to the more severe adverse effects and cost associated 
with these agents ( Beck  2018).  Dermavant has developed an effective , steroid -free, locally acting, 
cosmetically elegant topi[INVESTIGATOR_790852] a 
treatment -free remittive period.  Application of the product to plaque PSO in the head and neck region was 
permitted i n the Phase 3 registrational trials to assess tolerability, but efficacy was not specifically evaluated 
in this region . 
VTAMA (tapi[INVESTIGATOR_191752]) cream, 1% was approved by [CONTACT_319550] 2022 for the treatment of plaque PSO in 
adults. Tolerability in sensitive are as was excellent in Phase 3 pi[INVESTIGATOR_790853] -term extension 
study for a total duration of up to 52 weeks ( Lebwohl  2021; data on file). This study will further assess 
efficacy and safety of VTAMA (tapi[INVESTIGATOR_191752]) cream , 1% when used to treat head and neck PSO. 
  
DMVT -505 (tapi[INVESTIGATOR_191752])  IND 104601  
Dermavant Sciences , Inc.  Clinical Study  Protocol  
Confidential  Page | 10 Overall Design Synopsis:   
Brief Summary:   
The purpose of this open -label study is to evaluate the efficacy and safety of tapi[INVESTIGATOR_191753], 1% in adults 
with plaque PSO occurring in the head and neck region.  A target plaque PSO lesion in the head and neck 
region will be identified at Baseline , and efficacy of tapi[INVESTIGATOR_790854] a PGA evaluation.  
  Safety 
and tolerability will be assessed by [CONTACT_790868]. Application instructions will be reviewed at all clinic visits during the study, except during the 
final treatment/end -of-study visits.  Participants will be instructed to apply cream QD to all affected areas on 
the head and neck, including the target lesion.   Cream should be applied to newly appearing areas on the head 
and neck as well as areas in this region that improve or clear during the study.  Participant s may apply cream 
to any other lesions on the body although efficacy will only be assessed at the target lesion (PGA)  
.  Participants will apply sufficient cream to cover completely each lesion with a 
thin layer of medica tion and will record the time of application in a daily diary provided by [CONTACT_3452]. 
Participants will be instructed to maintain the approximate dosing time chosen at the beginning of the study 
for their full study participation . 
Number of Participant s:  
Approximately 30 participants will be enrolled.  
Note:   Enrolled means participants  agreement to participate in a clinical study following completion of the 
informed consent process and screening .  Potential participants who are screened for the purpose  of 
determining eligibility for the study, but do not participate in the study, are not considered enrolled, unless 
otherwise specified by [CONTACT_760] .  A participant will be considered enrolled if the informed consent is not 
withdrawn prior to participat ing in any study activity after screening .   
Study Arms and Duration:   
VTAMA (tapi[INVESTIGATOR_191752]) cream, 1%  is a white to off -white cream containing 1% weight/weight (10  mg/g) 
tapi[INVESTIGATOR_191752], supplied in 60 -gram tubes .  VTAMA is to be administered by [CONTACT_790869][INVESTIGATOR_106014] a thin layer to affected areas in accordance with instructions in the USPI.  
Dosing may be interrupted if deemed necessary by [CONTACT_790870]. 
Study duration : 
• The study duration will be up to 17 weeks.  
• The treatment duration will be up to 12 weeks . 
• The follow -up period  will be up to [ADDRESS_1090061] observation 

DMVT -505 (tapi[INVESTIGATOR_191752])  IND 104601  
Dermavant Sciences , Inc.  Clinical Study  Protocol  
Confidential  Page | [ADDRESS_1090062] method to impute missing data    
 
Efficacy and Safety Analyses  
Demographics  and baseline characteristics, efficacy , and all safety assessments  
 will be summarized descriptively , no statistical 
comparisons will be performed .  Continuous data will be summarized by [CONTACT_790871] , mean, SD, 
median, minimum, and maximum , and categorical data will be summarized by [CONTACT_790872] .  The 95% confidence intervals will be reported as appropriate .  Median time to event analyses 
will use the Kaplan -Meier product limit method (if estimable).  
Determination of Sample Size  
The sample size for this study is based on clinical considerations only. No formal sample size calculation will 
be performed. A total of 30 participants is planned for this study which is considered adequate to evaluate the 
efficacy and safety for the treatment of plaque PSO occurring in the head a nd neck region . 
Data Monitoring/Other Committee:  
No data monitoring committee has been appointed for this study .

DMVT -505 (tapi[INVESTIGATOR_191752])  IND 104601  
Dermavant Sciences , Inc.  Clinical Study  Protocol  
Confidential  Page | 15 2 Introduction   
VTAMA (tapi[INVESTIGATOR_191752]) cream, 1% was approved by [CONTACT_319550] 2022 for the treatment of plaque PSO in 
adults .  Tolerability in sensitive areas, including the face , was  excellent in Phase 3 pi[INVESTIGATOR_790855]-term extension study for a total duration of up to 52 weeks ( Lebwohl  2021; data on file) .   
2.1 Study Rationale   
This study will further assess efficacy and safety of VTAMA (tapi[INVESTIGATOR_191752]) cream, 1%  when used to treat PSO in 
the head and neck region .   
2.2 Background   
Occurrence  in the head and neck region is common  among patients with plaque PSO .  Scalp involvement 
occurs in 45 % to 56% of individuals with PSO,  and facial PSO typi[INVESTIGATOR_790846] a younger age and is 
estimated to affect nearly 50% of patients with PSO (Bagel  2018 ; Merola  2018).  The majority of patients 
with facial PSO also have scalp involvement ( Dopytalska  2018).  Scalp PSO can cause patients to feel 
embarrassed and self -conscious .  Facial PSO can be even more devastating because it cannot be hidden with 
clothing.  Despi[INVESTIGATOR_790847], disease in this area can result in considerable psychosocial 
challenges th at are not captured by [CONTACT_790867].   
Topi[INVESTIGATOR_790848]; however, due to the 
safety profile , their use is limited to only short -term therapy.  Other topi[INVESTIGATOR_790856]  D 
analogs offer better safety profiles but with moderate efficacy.  The use of any topi[INVESTIGATOR_790850] ( Mosca 2021 ).  
Because  many commonly used topi[INVESTIGATOR_790851], lack of adherence is an issue that compounds the lack of efficacy and 
poor safety profiles associated with these the rapi[INVESTIGATOR_014].  Systemic treatment, such as b iologics  and oral therapy, is 
reserved for the more severe and resistant cases due to the more severe adverse effects associated with 
systemic treatment ( Beck  2018).  There is a clear medic al need for an effective, steroid -free, locally acting 
topi[INVESTIGATOR_790857] a treatment -free remittive 
period given the challenges of treating this area.  
VTAMA (tapi[INVESTIGATOR_191752]) cream, 1% is a novel, cosmetically elegant, steroid -free topi[INVESTIGATOR_790858], thus, has the potential to meet the need in patients  with plaque PSO in the head and neck region .   
Application of the product to plaque PSO in the head and neck region  was permitted in the Phase  [ADDRESS_1090063] application of 
VTAMA to the scalp .  A detailed description of the chemistry, pharmacology, efficacy, and safety of 
VTAMA (tapi[INVESTIGATOR_191752]) cream, 1%  is provided in the IB. 
2.3 Benefit/Risk Assessment   
More detailed information about the known and expected benefits and risks and reasonably expected AEs of 
VTAMA (tapi[INVESTIGATOR_191752]) cream, 1%  may be found in the IB . 
DMVT -505 (tapi[INVESTIGATOR_191752])  IND 104601  
Dermavant Sciences , Inc.  Clinical Study  Protocol  
Confidential  Page | 16 2.3.1 Risk Assessment   
No ma jor safety concerns were identified during the development program ; no deaths or SAEs were 
considered related to VTAMA (tapi[INVESTIGATOR_191752]) cream, 1% .  Most AEs were mild localized skin reactions of a type 
commonly observed and managed by [CONTACT_83190] .  A low inc idence of safety issues, serious or 
non-serious, were observed .  The common AEs  associated with the administration of VTAMA (tapi[INVESTIGATOR_191752]) 
cream, 1%  in the clinical trials for plaque PSO were folliculitis, contact [CONTACT_8748], and headache .  Folliculitis 
event s were generally mild and well tolerated and did not worsen or progress over time with continued 
treatment .  The vast majority of participants  elected to continue with VTAMA (tapi[INVESTIGATOR_191752]) cream, 1% , 
suggesting the perceived benefit outweighs the burden of fo lliculitis .  See Section  10.3.[ADDRESS_1090064] dermatitis .   
2.3.2 Benefit Assessment   
VTAMA (tapi[INVESTIGATOR_191752]) cream is a novel, cosmetically elegant, steroid -free topi[INVESTIGATOR_790859] .  Benefits to participants  include  rapid improvement in signs and symptoms that 
persists with continued  use, the ability to achieve complete d isease clearance, and maintenance of disease 
control via a remittive effect after treatment discontinuation in a convenient once -daily topi[INVESTIGATOR_790860].  The remittive effect off therapy observed for VTAMA (tapi[INVESTIGATOR_191752]) cream, 1%  is a unique and 
differentiating attribute that, along  with durability on therapy, provide s patients  with a new option for 
long-term disease management .  These attributes are coupled with minimal systemic absorption and a 
favorable safety and tolerability profile.  
2.3.3 Overall Benefit Risk Conclusion   
Given  the measures taken to minimize risk  to participants participating in this study, the potential risks 
identified in association with VTAMA (tapi[INVESTIGATOR_191752]) cream  are justified by [CONTACT_790873] .  Please see  USPI [INVESTIGATOR_790861] -to-
date information.  
DMVT -505 (tapi[INVESTIGATOR_191752])  IND 104601  
Dermavant Sciences , Inc.  Clinical Study  Protocol  
Confidential  Page | 18 4 Study  Design   
4.1 Overall Design   
This is a single -group, open -label , multicenter study to evaluate the safety and efficacy of VTAMA 
(tapi[INVESTIGATOR_191752]) cream, 1% in the treatment of plaque PSO in the head and neck region .  Participants will treat 
plaque PSO in the head and neck region  with VTAMA (tapi[INVESTIGATOR_191752]) cream, 1 % QD for 12 wee ks.  Efficacy of 
the treatment of plaque PSO in the head and neck region  will be assessed with a PGA evaluation  of a target 
lesion selected as representative of the participant’s disease in the head and neck region.    
  Participants will be allowed 
to treat plaque PSO in other body areas  according to instructions provided in the USPI , but no assessments of 
efficacy will be performed outside of the head and neck  region .  Safety and tolerability will be assessed by 
[CONTACT_790874] : 
• The study duration will be up to 17 weeks.  
• The treatment duration will be up to 12 weeks . 
• The follow -up period will be up to 1 week . 
4.2 Scientific Rational e for Study Design   
The safety and efficacy of VTAMA (tapi[INVESTIGATOR_191752]) cream, 1% in the treatment of plaque PSO were established in 
Phase  3 studies, which included the treatment of sens itive areas .  This study is intended to broaden the 
understanding of the safety and efficacy of VTAMA (tapi[INVESTIGATOR_191752]) cream, 1% in the treatment of plaque PSO 
occurring in the head and neck region .  Efficacy and tolerability in th is area  will also be assessed .   
The PGA is a clinical tool for assessing the current state/severity of a participant ’s PSO at a given time  point .  
It is a static 5 -point morphological assessment of overall disease severity, as determined by [CONTACT_737], 
using the clinical charac teristics of erythema, scaling, and plaque thickness/elevation as guidelines; higher 
PGA scores represent more severe disease .  Improvements in PGA generally correlate with improvements in 
quality of life.  A target plaque PSO lesion in the head and neck r egion will be identified at Baseline and 
efficacy of tapi[INVESTIGATOR_790854] a PGA evaluation.  The primary endpoint will assess the percentage 
of participants who achieve a PGA (target lesion) score of clear (0) or almost clear (1) with a ≥  2-grade 
improvement from Baseline at Week  12.  This type of endpoint is well established as a means of measuring 
the success of treatments in plaque PSO .  The secondary endpoint will assess the t ime to achieve a PGA  
(target lesion)  score of 0 or 1 , as onset of a ction is incredibly important to patients in the clinic.   
 
 
4.3 Justification for Dose   
The FDA -approved dosing regimen for VTAMA (tapi[INVESTIGATOR_191752]) cream, 1% for the treatment of plaque PSO  is 
QD dosing and will be followed in this study .  This regimen is based on the evaluation of various tapi[INVESTIGATOR_790862] s regimen in Phase  [ADDRESS_1090065] participant in t he study .   

DMVT -505 (tapi[INVESTIGATOR_191752])  IND 104601  
Dermavant Sciences , Inc.  Clinical Study  Protocol  
Confidential  Page | 19 5 Study Population   
Prospective approval of protocol deviations to recruitment and enrollment criteria, also known as protocol 
waivers or exemptions, is not permitted.  
5.1 Inclusion Criteria   
Participants are eligible to be included in the study only if all of the following criteria apply:  
Age 
1. Participant must be 18 years of age or older , at the time  of signing the informed consent.  
Type of Participant and Disease Characteristics  
2. Participants with clinical diagnosis of plaque PSO, including lesion (s) in the head and neck region  and 
stable disease in the head and neck region  for at least 3 months prior to the study  
3. Participant has a plaque PSO lesion in the head and neck region that is  suitable for evaluation  as the 
target lesion  and has a PGA (target lesion) score  of 2 (mild), 3 (moderate) , or 4 (severe)  at Screening 
and Baseline .   
Sex an d Contraceptive/Barrier Requirements  
Contraceptive use by [CONTACT_790875].  
4. Female participants:  
A female participant is eligible to  participate if she is not pregnant or breastfeeding, and one of the 
following conditions applies:  
• Is a WONCBP as defined in Appendix 4  Contraceptive and Barrier Guidance  
OR 
• Is a WOCBP and using an acceptable contraceptive  method as described in Appendix [ADDRESS_1090066] .  The Investigator  should evaluate the potential for contraceptive method failure ( e.g., 
noncompliance, recently initiated) in relationship to the first dose of study product ). 
o A WOCBP must have a negative urine pregnancy test before the first dose of study product , 
see Sec tion 8.3.1  Pregnancy Testing .   
o The Investigator  is responsible for review of medical history, menstrual history, and recent 
sexual activity to decr ease the risk for inclusion of a woman with an early undetected 
pregnancy.  
Informed Consent  
5. Capable of giving signed informed consent as described in Appendix 1  which includes compliance with 
the requirements and restrictions listed in the ICF and in this protocol ; written informed consent must be 
obtained prior to any study -related procedures . 
DMVT -505 (tapi[INVESTIGATOR_191752])  IND 104601  
Dermavant Sciences , Inc.  Clinical Study  Protocol  
Confidential  Page | 20 5.2 Exclusion Criteria   
Participants are excluded from the study if any of the following criteria apply:  
Medical Conditions  
1. Diagnosis of a type of psoriasis other than plaque  PSO 
2. Any sign of infection of any of the psoriatic lesions  
3. Concurrent signific ant dermatologic or inflammatory condition other than plaque PSO that, in the 
Investigator’s opi[INVESTIGATOR_1649], would make it difficult to interpret data or assessments during the study  
4. A history of or ongoing serious illness or medical, physical, or psychiatric con dition(s) that, in the 
Investigator’s opi[INVESTIGATOR_1649], may interfere with participation in the study and ability to understand and give 
informed consent  
5. History of sensitivity to the study product , or components thereof , or a history of drug or other allergy 
that, in the opi[INVESTIGATOR_24245], contraindicates participation in the study  
Prior/Concomitant Therapy  
6. Previous OR current use of VTAMA  
7. Use of any prohibited medication within the indicated period before the Baseline visit  
NOTE:  Prohibited concomitant medications, therapy, etc., during the defined period are as listed in the 
bullets below .  If a participant  requires any of these medications throughout the study period, he/she 
may be excluded from or discontinued from the study.  
• Minimum of 5 half -lives for biologic agents: e.g., 12 months for rituximab; 8 months for 
ustekinumab; 5 months for secukinumab , risankizumab,  or tildrakizumab ; 12 weeks for 
golimumab  or guselkumab ; 10 weeks for ixekizumab  or infliximab ; 8 weeks for infliximab, 
adalimumab, alefacept , or brodalumab ; and 4 weeks for etanercept  
• Four  weeks for systemic treatments: deucravacitinib, cyclosporin, interferon, methotrexate, 
apremilast, tofacitinib, mycophenolate, thioguanine, hydroxyurea, sirolimus, azathiopri ne, other 
systemic immunosuppressive or immunomodulating agents, fumaric acid derivatives, vitamin  D3 
and analogs (>  5000  IU / day), retinoids ( e.g., acitretin, isotretinoin), psolarens, corticosteroids, or 
adrenocorticotropic hormone analogs  
• Two weeks for  immunizations with a live viral component; drugs known to possibly worsen PSO, 
such as beta -blockers ( e.g., propranolol), lithium, iodides, angiotensin -converting enzyme 
inhibitors, and indomethacin, unless on a stable dose for >  12 weeks  
• One week for medicated shampoos containing corticosteroids, vitamin D analogs, salicylic acid, or 
coal tar and 2 weeks for topi[INVESTIGATOR_8580]  
• With the exception of non -medicated emollients, [ADDRESS_1090067], antihistamin es, immunomodulators, anthralin (dithranol), vitamin  D 
derivatives ( e.g., calcipotriene, calcipotriol), retinoids (Note:  4 weeks for tazarotene), or coal tar  
NOTE:  If participants  are on a stable regimen of non -medicated emollient(s), they may continue 
to use the same emollient(s) on nonlesional skin during the study .   
DMVT -505 (tapi[INVESTIGATOR_191752])  IND 104601  
Dermavant Sciences , Inc.  Clinical Study  Protocol  
Confidential  Page | 21 Prior/Concurrent Clinical Study Experience  
8. Current enrollment OR past participation in another investigational study in which tapi[INVESTIGATOR_790863]  
9. The participant  has received an inv estigational product within the following time period prior to the first 
dosing day in the current study:   [ADDRESS_1090068]  (whichever is longer).  
Other Exclusion Criteria  
10. UV light therapy or prolonged exposure to natural or artificial sources of UV radiation ( e.g., 
phototherapy, tanning beds/booths, or therapeutic sunbathing) within 4 weeks prior to the Baseline visit 
and/or plans to have such exposures during the study which could potentially impact the participant 's 
PSO (as determined by [CONTACT_737]).  
5.[ADDRESS_1090069]  Application  
• Participants will be instructed to main tain the approximate dosing time chosen at the beginning of 
the study for their full study participation . 
• Participants should avoid swimming, bathing, showering, or strenuous activities for at least 2  hours 
after application . 
• If the participant elects to a pply study product  in the evening , the dose should be applied at least 
30 minutes prior to bedtime.  
5.4 Screen Failures   
A screen failure occurs when a participant who has consented to participate in the clinical study is not 
subsequently entered in the study .  A minimal set of screen failure information is required to ensure 
transparent reporting of screen failure participants to meet the CONSORT publishing requirements and to 
respon d to queries from regulatory authorities .  Minimal information includes demography, screen failure 
details, eligibility criteria, and any AE s. 
Individuals who do not meet the criteria for participation in this study (screen failure) may be rescreened  
1 time.  Rescreened participants should be assigned a new participant number . 
5.5 Criteria for Temporarily Delaying  Enrollment   
Not applicable  
DMVT -505 (tapi[INVESTIGATOR_191752])  IND 104601  
Dermavant Sciences , Inc.  Clinical Study  Protocol  
Confidential  Page | 22 6 Study Intervention(s) and Concomitant Ther apy  
Study product s are all prespecified, investigational and non -investigational medicinal products, medical 
devices , and other interventions (e.g., surgical and behavioral) inte nded to be administered to the study 
participants during the study conduct.  
6.1 Study Intervention(s) Administered   
Table  1: Study Intervention(s) Administered   
Intervention 
Name  [CONTACT_790897] (tapi[INVESTIGATOR_191752]) cream, 1%  
Intervention 
Description  A thin layer of cream (tapi[INVESTIGATOR_191752] 1%) applied to lesions QD  
Type  Drug 
Dose 
Formulation  Cream  
Unit Dose 
Strength(s)  Cream, 1%  
Dosage 
Level(s)  Total dosage is d ependent on BSA affected . 
Route of 
Administration  Topi[INVESTIGATOR_790864]/AxMP  IMP  
Sourcing  Provided centrally by [CONTACT_790876] (tapi[INVESTIGATOR_191752]) cream, 1%  will be provided in 60 -g commercial tubes and labeled to be distributed in the 
participating country and will meet all applicable requirements.  
Current/  
Former 
Names /Aliases  DMVT -505, formerly known as [COMPANY_004]2894512A, [COMPANY_004] 2894512, STI -1001, WBI -1001 , or JTE -061 
AxMP  = auxiliary medical product ; BSA  = body surface area; [COMPANY_004]  = GlaxoSmithKline ; IMP = investigational medicinal product ; 
NIMP  = non-investigational medical product ; QD  = once daily  
Table  2: Study Arm(s)   
Arm Title  VTAMA (tapi[INVESTIGATOR_191752]) cream, 1%  
Arm Type  Experimental ; open -label  
Arm 
Description  Participants will apply sufficient study product  to completely cover each lesion with a thin layer  QD for 
[ADDRESS_1090070]  should be applied to newly 
appearing areas on the head and neck as well as areas in this region that improve or clear during the study . 
Participants may treat plaque PSO in other areas; however, improvement of PSO in these areas will not be 
included in any efficacy analyses.  
Participants will be instructed to maintain the same  approximate dosing time chosen at the beg inning of the 
study for their full study participation . 
PSO = psoriasis; QD  = once daily . 
6.[ADDRESS_1090071] confirm appropriate conditions ( e.g., temperature) have been 
maintained during transit for all study product  received, and any discrepancies are reported and resolved 
before use of the study product . 
2. Only participants enrolled in the stud y may receive study product , and only authorized site staff may 
supply  study product .   
DMVT -505 (tapi[INVESTIGATOR_191752])  IND 104601  
Dermavant Sciences , Inc.  Clinical Study  Protocol  
Confidential  Page | [ADDRESS_1090072] be stored in a secure, environmentally controlled, and monitored (manual or 
automated) area in accordance with the labeled storage conditions wit h access limited to the Investigator  
and authorized site staff.  
4. The Investigator  or authorized site staff is responsible for study product  accountability, reconciliation, 
and record maintenance ( i.e., receipt, reconciliation, and final disposition records) . 
5. Further guidance and information for the final disposition of unused study product s are provided in the 
Study Reference Manual . 
6.[ADDRESS_1090073] until the next visit .  All tubes, including e mpty tubes , will be collected  at 
Visit  7.  Deviation(s) from the prescribed dosage regimen should be recorded.  
A record of t he quantity of study product  dispensed to and administered by [CONTACT_790877] .  Intervention start and stop dates, 
including dates for temporary interruptions , will also be record ed. 
6.6 Dose Modification   
Dosing may be  temporarily  interrupted if deemed necessary by [CONTACT_790870]. 
6.7 Continued Access to Study Intervention after the End of  the Study   
VTAMA (tapi[INVESTIGATOR_191752]) cream, 1% is commercially  available for the treatment of plaque PSO.  
6.[ADDRESS_1090074] will be considered an overdose .  
Ingestion of a 60-gram  tube of VTAMA (tapi[INVESTIGATOR_191752]) cream, 1%  would result in an oral dose of 600  mg of 
tapi[INVESTIGATOR_191752] . 
DMVT -505 (tapi[INVESTIGATOR_191752])  IND 104601  
Dermavant Sciences , Inc.  Clinical Study  Protocol  
Confidential  Page | 24 The Sponsor does n ot recommend specific treatment for an overdose; however, in the event of an overdose, 
the Investigator (or treating physician) should do the following:  
• Contact [CONTACT_191841]  
• Closely monitor the participant  for AEs/SAEs and laborator y abnormalities  
• Provide general symptomatic treatment as necessary  
• Document the quantity of the excess dose as well as the duration of the overdosing  
Decisions regarding dose interruptions or modifications following an overdose will be made by [CONTACT_790878] . 
6.9 Prior and Concomitant Therapy   
Any medication or vaccine , including over the counter  or prescription medicines, recreational drugs, vitamins, 
and/or herbal supplements , as well as non -medicated emollients, that the participant is utilizing  at the time of 
consent or receives during the study must be recorded along with:  
• Reason for u se  
• Dates of administration including start and end dates  
• Dosage information including dose and frequency  
The medical monitor should be contact[CONTACT_31182].  
Concomitant medications for medical treatme nt of other conditions are allowed, under the condition that the 
dosage and administration of these treatments are not planned to change from the Baseline visit to the 
completion of the study or discontinuation, and that the medication is not a prohibited medication as described 
in Section  5.2.   
In the event of skin infection, topi[INVESTIGATOR_402228]; however,  study 
product  must not be applied to the area until the skin infection is healed.  
Participant s may use non -medicated shampoos (must not contain corticosteroids, vitamin D analogs, salicylic 
acid, or coal tar) .  If participants are on a stable regimen of non -medicated emollient(s), they may continue to 
use the same emollient(s) on nonlesional skin during the study.  The same emollient should be used 
throughout participation in the study .   
DMVT -505 (tapi[INVESTIGATOR_191752])  IND 104601  
Dermavant Sciences , Inc.  Clinical Study  Protocol  
Confidential  Page | 25 7 Discontinuation of Study  Intervention and Participant Discontinuation/Withdrawal   
Discontinuation of specific sites or of the study as a whole are detailed in Appendix [ADDRESS_1090075] been observed following treatment with  VTAMA (tapi[INVESTIGATOR_191752]) cream, 1% 
(see Section  2.3.1 ).  After cessation of exposure, dermatological reactions generally subside spontaneously or 
with topi[INVESTIGATOR_12969] . 
In this study , treatment of plaque PSO in the head and neck region with study product  may be temporarily 
interrupted for dermatological reactions .  If treatment is interrupted due to a safety issue, the Medical Monitor 
will be contact[INVESTIGATOR_530],  and the event documented in the eCRF.  
See Section  10.3.[ADDRESS_1090076]  is temporarily interrupted  due to dermatological reactions, treatment may be resumed at the 
Investigator’s discretion when the reaction has subsided.  
7.2 Participant Discontinuation/Withdrawal from the Study   
• A participant may withdraw from the study at any time at the participant’s own request for any 
reason (or without providing any reason).  
• A participant may be withdrawn at any time at the discretion of the Investigator  for safety or 
compliance reasons .   
• At the time of discontinuing from the study, if possible, an early discontinuation visit should be 
conducted, as shown in the SoA .  See SoA for data to be collected at the time of study 
discontinuation and follow -up and for any further evaluations that need to be completed.  
• The participant will be permanently discontinued from the study product  and the study at that time.  
• If the participant withdraws consent for disclosure of future information, the Sponsor  may retain 
and con tinue to use any data collected before such a withdrawal of consent.  
• If a participant withdraws from the study, the participant may request destruction of any samples 
taken and not tested, and the Investigator  must document this in the site study records.  
7.[ADDRESS_1090077] to follow -up if the participant repeatedly fails to return for scheduled 
visits and is unable to be contact[CONTACT_56821]. 
DMVT -505 (tapi[INVESTIGATOR_191752])  IND 104601  
Dermavant Sciences , Inc.  Clinical Study  Protocol  
Confidential  Page | [ADDRESS_1090078] be taken if a participant fails to return to the clinic for a required study visit:  
• The site must attempt to contact [CONTACT_185610], 
counsel the participant on the impor tance of maintaining the assigned visit schedule , and ascertain 
whether the participant wishes to and/or should continue in the study.  
• Before a participant is deemed lost to follow -up, the Investigator  or designee must make every 
effort to regain contact w ith the participant (where possible, 3 telephone calls, and if necessary, a 
certified letter to the participant’s last known mailing address or local equivalent methods) .  These 
contact [CONTACT_13140]’s medical record.  
• Should the participant continue to be unreachable, the participant will be considered to have 
withdrawn from the study .   
 
DMVT -505 (tapi[INVESTIGATOR_191752])  IND 104601  
Dermavant Sciences , Inc.  Clinical Study  Protocol  
Confidential  Page | 27 8 Study Assessments and Procedures   
• Study procedures and t heir timing are summarized in the SoA .  Protocol waivers or exemptions are 
not allowed.  
• Adherence to the study design requirements, including those specified in the SoA, is essential and 
required for study conduct.  
• All screening evaluations must be complet ed and reviewed to confirm that potential participants 
meet all eligibility criteria .  The Investigator  will maintain a screening log to record details of all 
participants screened and to confirm eligibility or record reasons for screening failure, as 
applicable.  
• In the event of a significant study -continuity issue ( e.g., caused by a pandemic), alternate strategies 
for participant visits, assessments, medication distribution , and monitoring may be implemented by 
[CONTACT_14317] , as per local  health authority/ethics requirements .   
8.[ADDRESS_1090079] utilize an IRB - or IEC -approved 
consent form for documenting written informed consent .  Each informed consent will be appropriately signed 
and dated by [CONTACT_790879].  
8.1.2 Demographics   
Demographic information collected will include age, sex, race, ethnicity, and Fitzpatrick skin type  (Table  3).   
Table  3: Fitzpatrick Skin Type Scale   
Skin Type  Sunburn Tendency  Suntan Tendency  
Type I  Always burns easily  Never tan  
Type II  Always burns easily  Tans slightly  
Type III  Burns moderately  Tans gradually  
Type IV  Burns minimally  Tans moderately  
Type V  Rarely burns  Tans profusely  
Type VI  Never burns  Tans profusely  
8.1.3 Medical History   
Medical history will be collected to ensure participant s are eligible for participation in the study (per inclusion 
Section  5.1 and exclusion Section  5.2 criteria) .   
Data collected will include year of  plaque  PSO diagnosis, allergic conditions,  and CV medical history and risk 
factors (medical conditions, and family history of premature CV disease) .   
If a participant  has previously tested positive for COVID -19 or has previously received a COVID -19 vaccine, 
it shoul d be documented in the participant ’s medical history.  
8.1.[ADDRESS_1090080] the time of app lication in a daily 
diary provided by [CONTACT_3452] .   
DMVT -505 (tapi[INVESTIGATOR_191752])  IND 104601  
Dermavant Sciences , Inc.  Clinical Study  Protocol  
Confidential  Page | 28 Application Instructions  
Participants will be instructed to:  
• Treat all lesions in the head and neck region , both newly appearing lesions and lesions that have 
improved or cleared during the study  
Note :  Participants may treat plaque PSO in other areas  according to instructions provided in the 
USPI .  No other treatment for scalp PSO is permitted during the study.  
• Apply cream  to dry, clean skin in an amount sufficient to completely cover each lesion with  a thin 
layer  
• Continue to lightly rub any residual cream visible on the disease -affected skin until it is no longer 
visible  
• Wash hands after application, unless treating lesions on the hands or fingernails  
Timing  of Application  
Participants will be instructed to : 
• Maintain the approximate time of day for dosing at home throughout  their full study participation  
• Record the time of application in the daily diary  
• Apply cream  at least 30 minutes prior to bedtime  if their chosen application time is in the e vening  
• Avoid swimming, bathing, showering, or strenuous activities for at least 2 hours after application  
Missed Doses  
A missed daily dose  will be recorded as a protocol deviation .   
Participants will be instructed that if a dose is missed,  they should  continue dosing the next day and should 
not apply more than QD to make up for the missed dose on the previous day.  
8.2 Efficacy Assessments    
Planned time  points for all efficacy assessments are provided in the SoA.  
8.2.1 Efficacy Assessments Completed by [CONTACT_790880] -observer variability, Investigators and evaluators/raters will be trained on each of the 
required assessments during an Investigator meeting, site initiation visit, and/or utilizing online assessments 
before enrolling subjects at their study site .  Only train ed evaluators/raters are permitted to perform the 
efficacy assessments .  To the fullest extent possible, the same Investigator (or designated evaluator/rater) will 
perform all efficacy assessments for an individual subject throughout the study .  If it is n ot possible for the 
same evaluator/rater to continue performing assessments, it is recommended that the primary and subsequent 
evaluator/rater both examine and discuss their respective scoring during at least 1 visit.  
[IP_ADDRESS]  Physician Global Assessment  of Target Lesion   
The PGA is a clinical tool for assessing the current state/severity of a participant ’s PSO at a given time  point .  
It is a static 5 -point morphological assessment of overall disease severity, as determined by [CONTACT_737], 
using the clinical characteristics of erythema, scaling, and plaque thickness/elevation as guidelines; higher 
PGA scores represent more severe d isease (see Appendix  5).   
In this study , the PGA should be used only to assess the target plaque PSO lesion in the head and neck region . 
DMVT -505 (tapi[INVESTIGATOR_191752])  IND 104601  
Dermavant Sciences , Inc.  Clinical Study  Protocol  
Confidential  Page | 29    
 
 
 
 
 
 
 
   
 
  
  
 
 
  
    
 
  
 
   
 
  
 
 
 
  
 
   
 
 
   
8.3 Safety Assessments   
Planned time  points for all safety assessments are provided in  the SoA.  

DMVT -505 (tapi[INVESTIGATOR_191752])  IND 104601  
Dermavant Sciences , Inc.  Clinical Study  Protocol  
Confidential  Page | 31 8.4.3 Follow -up of AEs and SAEs   
After the initial AE/SAE report, the Investigator  is required to proactively follow each participant at 
subsequent visits/contacts .  All SAEs (as defined in Appendix 3) will be followed until resolution, 
stabilization, t he event is otherwise explained, or the participant is lost to follow -up (as defined in 
Section  7.3).  Further information on follow -up procedures is provided in Appendix 3 . 
8.4.4 Regulatory Reporting Requirements for SAEs   
• Prompt notification by [CONTACT_184159] a study 
product  under clinical  investigation are met.  
• The Sponsor  has a legal responsibility to notify both the local regulatory authority and other 
regulatory agencies about the safety of a study product  under clinical investigation .  The Sponsor  
will comply with country -specific regu latory requirements relating to safety reporting to the 
regulatory authority, IRBs/IECs, and Investigator s. 
• An Investigator  who receives an Investigator  safety report describing an SAE or other specific 
safety information ( e.g., summary or listing of SAEs)  from the Sponsor  will review , acknowledge 
electronically, and  retain a copy within the Study Reference Manual and will notify the IRB/IEC, 
if appropriate according to local requirements.  
• Investigator safety reports must be prepared for S[LOCATION_003]Rs according to  local regulatory 
requirements and Sponsor  policy and forwarded to Investigator s as necessary.  
8.4.5 Pregnancy   
• Details of all pregnancies  in female participants and, if indicated, female partners of male 
participants will be collected after the start of study product  and until the last dose of study 
product . 
• If a pregnancy is reported, the Investigator  will record pregnancy information on t he appropriate 
form and submit it to the Sponsor  within 24 hours of learning of the female participant  or female 
partner of a male participant (after obtaining the necessary signed informed consent from the 
female partner) pregnancy.  
• While pregnancy itself  is not considered to be an AE or SAE, any pregnancy complication or 
elective termination of a pregnancy for medical reasons will be reported as an AE or SAE.  
• Abnormal pregnancy outcomes ( e.g., spontaneous abortion, fetal death, stillbirth, congenital 
anom alies, ectopic pregnancy) are considered SAEs and will be reported as such.  
• The participant/pregnant female partner will be followed to determine the outcome of the 
pregnancy .  The Investigator  will collect follow -up information on the participant/pregnant  female 
partner and the neonate,  and the information will be forwarded to the Sponsor . 
• Any poststudy pregnancy -related SAE considered reasonably related to the study product  by [CONTACT_790881]  8.4.4.  While the Investigator  is 
not obligated to actively seek this information in former study participants/pregnant female 
partner, he or she may learn of an SAE through spontaneous reporting.  
• Any female participant who becomes pregnant while  participating in the study will discontinue 
study product  or be withdrawn from the study.  
8.5 Pharmacokinetics   
Pharmacokinetic  parameters are not evaluated in this study.  
DMVT -505 (tapi[INVESTIGATOR_191752])  IND 104601  
Dermavant Sciences , Inc.  Clinical Study  Protocol  
Confidential  Page | 32 8.6 Pharmacodynamics   
Pharmacodynamic  parameters are not evaluated in this study.  
8.7 Genetics   
Genetics are not evaluated in this study.  
8.8 Biomarkers   
Biomarkers are not evaluated in this study.  
8.9 Immunogenicity Assessments   
Immunogenicity  is not evaluated in this study.  
8.10 Health Economics    
Health economics parameters are not evaluated in this study.  
 
DMVT -505 (tapi[INVESTIGATOR_191752])  IND 104601  
Dermavant Sciences , Inc.  Clinical Study  Protocol  
Confidential  Page | 33 9 Statistical Considerations   
The statis tical analysis plan will be finalized prior to database lock and will include a more technical and 
detailed description of the statistical analyses described in this section .   
All study data will be summarized using descriptive statistics .  Categorical endpoints will be summarized 
using frequency and percentage (e.g., gender, race) .  Continuous endpoints will be summarized using number 
of observations , mean, SD, median, minimum, and maximum .  The 95% confidence intervals will also be 
reported as appropriat e.  All efficacy and safety data will be listed by [CONTACT_3445] .   
9.1 Statistical Hypothesis   
Not applicable .  Demographic and baseline characteristics, e fficacy, safety,   
 will be summarized descriptively .  No inferential testing will be performed.  
9.1.1 Multiplicity Adjustment   
Not applicable  
9.2 Analys is Sets   
Efficacy, safety,   collected will be summarized 
for the ITT population .   
Participant Analysis Set  Descripti on 
Intent -to-treat population  (ITT)  All participants enrolled in the study .  
9.3 Statistical Analyses   
9.3.1 General Considerations   
This study is intended to show that VTAMA (tapi[INVESTIGATOR_191752]) cream, 1%  has a favorable safety and efficacy profile 
when applied to lesions in the head and neck region  over a [ADDRESS_1090081] method to impute missing data    
 
9.3.2 Primary Endpoint Analysis   
The primary efficacy endpoint will be summarized descriptively with frequency count, percentage, and 
95% confidence interval.  
9.3.[ADDRESS_1090082] limit method will be used to estimate the median time to achieving a  target lesion 
PGA score of 0 or 1 with a ≥  2-grade improvement from Baseline (if estimable).  
9.3.4    
 
 
 

DMVT -505 (tapi[INVESTIGATOR_191752])  IND 104601  
Dermavant Sciences , Inc.  Clinical Study  Protocol  
Confidential  Page | 34 9.3.5 Safety Analyses    
   
The number and percent  of participants  with TEAEs will be summarized by [CONTACT_9313], and preferred  
term for all TEAEs ; all TEAEs by [CONTACT_9313], preferred term, and maximum CTCAE grade ; all 
TEAEs considered by [CONTACT_790882] ; SAEs ; TEAEs leading t o study product  
discontinuation ; and TEAEs leading to discontinuation from study . 
9.4 Interim Analysis   
Not applicable  
9.5 Sample Size Determination   
The sample size for this study is based on clinical considerations only .  No formal sample size calculation will 
be performed .  A total of 30 participants is planned for this study which is considered adequate to evaluate the 
efficacy  and safety for the treatment of plaque PSO in the  head and neck region . 

DMVT -505 (tapi[INVESTIGATOR_191752])  IND 104601  
Dermavant Sciences , Inc.  Clinical Study  Protocol  
Confidential  Page | 35 10 Supporting Documentation and Operational Considerations   
10.1 Appendix 1:  Regulatory, Eth ical, and Study Oversight Considerations   
10.1.1  Regulatory and Ethical Considerations   
• This study will be co nducted in accordance with the protocol and with the following:  
o Consensus ethical principles derived from international guidelines including the Declaration of 
Helsinki and Council for International Organizations of Medical Sciences international ethical 
guidelines  
o Applicable ICH GCP guidelines  
o Applicable laws and regulations  
• The protocol, protocol amendments, ICF, IB, and other relevant documents ( e.g., advertisements) 
must be submitted to an IRB/IEC by [CONTACT_790883] /IEC 
before the study is initiated.  
• Any amendments to the protocol will require IRB/IEC approval before implementation of changes 
made to the study design, except for changes necessary to eliminate an immediate hazard to study 
participants .   
• Protocols and  any substantial amendments to the protocol will require health authority approval 
prior to initiation (if applicable per country - or region -specific regulations) except for changes 
necessary to eliminate an immediate hazard to study participants.  
• The Investigator  will be responsible for the following, as applicable:  
o Providing written summaries of the status of the study to the IRB/IEC annually or more 
frequently in accordance with the requirements, policies, and procedures established by [CONTACT_5040]/IEC  
o Notify ing the IRB/IEC of SAEs or other significant safety findings as required by [CONTACT_1744]/IEC 
procedures  
o Providing oversight of the conduct of the study at the site and adherence to requirements of 
21 CFR, ICH guidelines, the IRB/IEC, European regulation 536/2014 fo r clinical studies, 
European Medical Device Regulation 2017/[ADDRESS_1090083] igators  and Sub-investigator s are responsible for providing 
information on financial interests during the course of the study and for 1 year after completion of the study.  
10.1.3  Informed Consent Process   
• The Investigator  or the Investigator ’s representative will explain the nature of the study, including 
the risks and benefits, to the potential  participant  and answer all questions regarding the study.  
• Potential participants must be infor med that their participation is voluntary . Participants  will be 
required to sign a statement of informed consent that meets the requirements of 21 CFR 50, local 
regulations, ICH guidelines, privacy and data protection requirements, where applicable, and th e 
IRB/IEC or study center.  
• The medical record must include a statement that written informed consent was obtained before 
the participant was enrolled in the study and the date the written consent was obtained .  The 
authorized person obtaining the informed consent must also sign the ICF.  
DMVT -505 (tapi[INVESTIGATOR_191752])  IND 104601  
Dermavant Sciences , Inc.  Clinical Study  Protocol  
Confidential  Page | 36 • Participants must be reconsented to the most current version of the ICF(s) during their 
participation in the study.  
• A copy of the ICF(s) must be provided to the participant.  
Participants who are rescreened are required to si gn a new ICF.  
10.1.4  Data Protection   
• Participants will be assigned a unique identifier by [CONTACT_1034] .  Any participant records or 
datasets that are transferred to the Sponsor  will cont ain the identifier only; participant names or 
any information which would make the participant identifiable will not be transferred.  
• The participant must be informed that their personal study -related data will be used by [CONTACT_790884] l data protection law .  The level of disclosure must also be explained to the 
participant who will be required to give consent for their data to be used as described in the 
informed consent  
• The participant must be informed that their medical records may b e examined by [CONTACT_35383] , by [CONTACT_99473]/IEC members, and by [CONTACT_6668].  
• The contract between Sponsor  and study sites specifies responsibilities  of the parties related data 
protection, including handling of data security breaches and respective communication and 
cooperation of the parties.  
• Information technology systems used to collect, process, and store study -related data are secured 
by [CONTACT_790885] l and organizational security measures designed to protect such data against accidental 
or unlawful loss, alteration, or unauthorized disclosure or access.  
10.1.5  Dissemination of Clinical Study Data   
Anonymized Clinical Study Reports will be disclosed as required by [CONTACT_12721].  
Study information and tabular study results will be posted on National Institutes of Health’s website 
www.clinicaltrials.gov and other publicly access ible sites .  Study results may be published in peer -reviewed 
publications or  presented at scientific meetings . 
Following an assessment of a rigorously defined research question from a third party, Dermavant may gran t 
access to analyzable datasets from this study through a secure system .   
10.1.6  Data Quality Assurance   
• All participant data relating to the study will be recorded on printed or electro nic CRFs unless 
transmitted to the Sponsor  or designee electronically ( e.g., laboratory data) .  The Investigator  is 
responsible for verifying that data entries are accurate and correct by [CONTACT_112247].  
• Guidance on completion  of CRFs will be provided in CRF completion guidelines . 
• The Investigator  must permit study -related monitoring, audits, IRB/IEC review, and regulatory 
agency inspections and provide direct access to source documents.  
• Monitoring details describing strategy, including definition of study critical data items and 
processes ( e.g., risk -based initiatives in operations and quality such as risk management and 
mitigation strategies and analytical risk -based monitoring), methods, responsibilities, and 
requirements, in cluding handling of noncompliance issues and monitoring techniques (central, 
remote, or on -site monitoring) are provided in the Study Reference Manual . 
• The Sponsor  or designee is responsible for the data management of this study, including quality 
checking  of the data.  
DMVT -505 (tapi[INVESTIGATOR_191752])  IND 104601  
Dermavant Sciences , Inc.  Clinical Study  Protocol  
Confidential  Page | 37 • The Sponsor  assumes accountability for actions delegated to other individuals ( e.g., contract 
research organizations).  
• Records and documents, including signed ICFs, pertaining to the conduct of this study must be 
retained by [CONTACT_14344] 15 years after study completion unless local regulations or 
institutional policies require a longer retention period .  No records may be destroyed during the 
retention period without the written approval of the Sponsor .  No records may be transferred to 
another location or party without written notification to the Sponsor . 
10.1.7  Source Documents   
• Source documents provide evidence for the existence of the participant and substantiate  the 
integrity of the data collected .  Source documents are filed at the Investigator ’s site.  
• Data reported on the CRF or entered in the eCRF that are transcribed from source documents must 
be consistent with the source documents or the discrepancies must be explained .  The Investigator  
may need to request previous medical records or transfer records, depending on the study .  Also, 
current medical records must be available.  
• Definition of what constitutes source data and its origin can be found in source data 
acknowledgment.  
• The Investigator  must maintain accurate documentation (source data) that supports the information 
entered in the eCRF.  
• The Sponsor  or designee will perform monitoring to confirm that data entered into the CRF by 
[CONTACT_790886], complete, and verifiable from source documents; that the 
safety and rights of participants are being protected; and that the study is being conducted in 
accordance with the currently approved protocol and any other study agreements, ICH GC P, and 
all applicable regulatory requirements.  
10.1.[ADDRESS_1090084] site activated and will be the study start date.  
Study/Site Termination  
The Sponsor  or designee reserves the right to close the study site or terminate the study at any time for an y 
reason at the sole discretion of the Sponsor .  Study sites will be closed upon study completion .  A study site is 
considered closed when all required documents and study supplies have been collected and a study -site 
closure visit has been performed.  
The Investigator  may initiate study -site closure at any time, provided there is reasonable cause and sufficient 
notice is given in advance of the intended termination.  
Reasons for the early closure of a study site by [CONTACT_790887]:  
For study termination:  
• Discontinuation of further study product  development  
For site termination:  
• Failure of the Investigator  to comply with the protocol, the requirements of the IRB/IEC or local 
health authorities, the Sponsor ’s proce dures, or GCP guidelines  
DMVT -505 (tapi[INVESTIGATOR_191752])  IND 104601  
Dermavant Sciences , Inc.  Clinical Study  Protocol  
Confidential  Page | 38 • Inadequate or no recruitment (evaluated after a reasonable amount of time) of participants by [CONTACT_3786]  
• Total number of participants included earlier than expected  
If the study is prematurely terminated or suspended, the Sponsor shall promptly inform the Investigator s, the 
IECs/IRBs, the regulatory authorities, and any contract research organization(s) used in the study of the 
reason for termination or suspension, as specified by [CONTACT_1214] .  The Investigator  
shall promptly inform the participant and should assure appropriate participant therapy and/or follow -up. 
10.1.9  Publication Policy   
• After conclusion of the study and without  prior written approval from the Sponsor , Investigator(s) 
in this study may communicate, orally present, or publish in scientific journals or other scholarly 
media the study results only after the following conditions have been met:  
• The study results in their entirety have been publicly disclosed by [CONTACT_790888] , in an abstract, manuscript, or presentation; OR  
• The study has been completed at all study sites for at least 1 year.  
• To allow the  Sponsor  to protect con fidential and proprietary information and to provide comments, 
any proposed publication or presentation meeting the criteria set forth in the bullet point 
immediately above will be submitted to the Sponsor  along with the respective scientific journal or 
presentation forum at least 30 days before submission of the proposed publication or presentation.   
Investigator (s) will comply with the Sponsor  request to delete references to its confidential and/or 
proprietary information (other than the study results) i n any paper or presentation and agrees to 
withhold publication or presentation for an additional 60 days to allow the Sponsor  or its affiliates 
obtain patent protection if deemed necessary.   
• No such communication, presentation, or publication of the study  results will include the 
Sponsor ’s confidential and/or proprietary information.  
• The Sponsor  will comply with the requirements for publication of study results.  In accordance 
with standard editorial and ethical practice, the  Sponsor  will generally support  publication of 
multicenter studies only in their entirety and not as individual site data.  In this case, a coordinating 
Investigator [INVESTIGATOR_12992].  
• Authorship will be determined by [CONTACT_27495].  
  
DMVT -505 (tapi[INVESTIGATOR_191752])  IND 104601  
Dermavant Sciences , Inc.  Clinical Study  Protocol  
Confidential  Page | 39 10.2 Appendix 2:  Clinical Laboratory Tests   
No clinical laboratory tests  will be performed in this study . 
  
DMVT -505 (tapi[INVESTIGATOR_191752])  IND 104601  
Dermavant Sciences , Inc.  Clinical Study  Protocol  
Confidential  Page | 40 10.3 Appendix 3:  AEs and SAEs:  Definitions and Procedures for Recording, Evaluating, Follow -up, 
and Reporting   
10.3.1  Definition of AE   
AE Definition  
• An AE is any untoward medical occurrence in a clinical study participant, temporally associated 
with the use of study product , whether or not considered related to the study product . 
• NOTE:  An AE can therefore be any u nfavorable and unintended sign (including an abnormal 
laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use 
of study product . 
Definition of Unsolicited and Solicited AE  
• An unsolicited AE is an AE that was not soli cited using a participant diary and that is 
communicated by a participant who has signed the informed consent .  Unsolicited AEs include 
serious and nonserious AEs.  
• Potential unsolicited AEs may be medically attended ( i.e., symptoms or illnesses requiring a  
hospi[INVESTIGATOR_059], emergency room visit, or visit to/by a healthcare provider) .  The participant will be 
instructed to contact [CONTACT_285147](s), as well as 
any events that, though not medically attended, are  of participant concern .  Detailed information 
about reported unsolicited AEs will be collected by [CONTACT_103089]’s records.  
• Unsolicited AEs that are not medically attended nor perceived as a concern by [CONTACT_790889].  
• Solicited AEs are predefined local and systemic events for which the participant is specifically 
questioned, and which are noted  by [CONTACT_139140].  
Events Meeting the AE Definition  
• Any abnormal laboratory test results (hematology, clinical chemistry, or urinalysis) or other safety 
assessments ( e.g., electrocardiogram , radiological scans, vital signs measurements), including 
those that worsen from baseline, considered clinically significant in the medical and scientific 
judgment of the Investigator  (i.e., not related to progression of underlying disease, or more severe  
than expected for the participant’s condition)  
• Exacerbation of a chronic or intermittent pre -existing condition including either an increase in 
frequency and/or intensity of the condition  
• New condition detected or diagnosed after study product  administrat ion even though it may have 
been present before the start of the study  
• Signs, symptoms, or the clinical sequelae of a suspected drug -drug interaction  
• Signs, symptoms, or the clinical sequelae of a suspected overdose of either study product  or a 
concomitant medication .  Overdose per se will not be reported as an AE/SAE unless it is an 
intentional overdose taken with possible suicidal/self -harming intent .  Such overdoses should be 
reported regardless of sequelae.  
• Lack of efficacy or failure o f expected pharmacological action per se will not be reported as an AE 
or SAE .  Such instances will be captured in the efficacy assessments .  However, the signs, 
symptoms, and/or clinical sequelae resulting from lack of efficacy will be reported as AE or S AE 
if they fulfill the definition of an AE or SAE.  
DMVT -505 (tapi[INVESTIGATOR_191752])  IND 104601  
Dermavant Sciences , Inc.  Clinical Study  Protocol  
Confidential  Page | 41 Events not Meeting the AE Definition  
• Any abnormal laboratory findings or other abnormal safety assessments that are associated with 
the underlying disease, unless judged by [CONTACT_790890]’s condition  
• The disease/disorder being studied or expected progression, signs, or symptoms of the 
disease/disorder being studied, unless more severe than expected for the participant’s condition  
• Medical or surgical proc edure ( e.g., endoscopy, appendectomy):  The condition that leads to the 
procedure is the AE . 
• Situations in which an untoward medical occurrence did not occur (social and/or convenience 
admission to a hospi[INVESTIGATOR_307])  
• Anticipated day -to-day fluctuations of pre -existing disease(s) or condition(s) present or detected at 
the start of the study that do not worsen  
10.3.[ADDRESS_1090085] medical occurrence that, at any dose, meets one or more of the criteria 
listed:  
a. Results in death  
b. Is life threatening  
The term life threatening in the definition of serious refers to an event in which the participant was at risk of 
death at the time of the event .  It does not refer to  an event, which hypothetically might have caused death, if 
it were more severe.  
c. Requires inpatient hospi[INVESTIGATOR_1081]  
• In general, hospi[INVESTIGATOR_12994] (usually involving at 
least an overnight stay) at the hospi[INVESTIGATOR_22771]/or treatment that 
would not have been appropriate in the physician’s office or outpatient setting .  Complications that 
occur during hospi[INVESTIGATOR_1084] .  If a complicatio n prolongs hospi[INVESTIGATOR_1085], the event is serious .  When in doubt as to whether hospi[INVESTIGATOR_490801], the AE should be considered serious.  
• Hospi[INVESTIGATOR_5187] a pre -existing c ondition that did not worsen from baseline 
is not considered an AE.  
d. Results in persistent or significant disability/incapacity  
• The term disability means a substantial disruption of a person’s ability to conduct normal life 
functions.  
• This definition is not  intended to include experiences of relatively minor medical significance such 
as uncomplicated headache, nausea, vomiting, diarrhea, influenza, and accidental trauma ( e.g., 
sprained ankle) that may interfere with or prevent everyday life functions but do not constitute a 
substantial disruption.  
e. Is a congenital anomaly/birth defect  
f. Is a suspected transmission of any infectious agent via an authorized medicinal product  
g. Other situations:  
• Medical or scientific judgment should be exercised by [CONTACT_790891] -threatening or result in death or hospi[INVESTIGATOR_790865] -505 (tapi[INVESTIGATOR_191752])  IND 104601  
Dermavant Sciences , Inc.  Clinical Study  Protocol  
Confidential  Page | 42 or may require medical or surgic al intervention to prevent one of the other outcomes listed in the 
above definition .  These events should usually be considered serious.  
o Examples of such events include invasive or malignant cancers, intensive treatment in an 
emergency room or at home for allergic bronchospasm, blood dyscrasias, convulsions not 
resulting in hospi[INVESTIGATOR_059], or development of intervention dependency or intervention abuse.  
10.3.3  Recording and Follow -Up of AE and/or SAE   
AE and SAE Recording  
• When an AE/SAE occurs, it is the responsibility of the Investigator  to review all documentation 
(e.g., hospi[INVESTIGATOR_1088], laboratory reports, and diagnostics reports) related to the event.  
• The Investigator  will the n record all relevant AE/SAE information.  
• It is not acceptable for the Investigator  to send photocopi[INVESTIGATOR_10914]’s medical records to 
the Sponsor  in lieu of completion of the required form.  
• There may be instances when copi[INVESTIGATOR_184120] r certain cases are requested by 
[CONTACT_12721] .  In this case, all participant identifiers, with the exception of the participant 
number, will be redacted on the copi[INVESTIGATOR_790866] . 
• The Invest igator  will attempt to establish a diagnosis of the event based on signs, symptoms, 
and/or other clinical information .  Whenever possible, the diagnosis (not the individual 
signs/symptoms) will be documented as the AE/SAE.  
•  
Assessment of Severity  
The Investigator  will make an assessment of severity for each AE and SAE reported during the study 
according to the National Cancer Institute CTCAE, v . 5.0, 2017 .  For terms not specified with the CTCAE, 
the cri teria in Table  4 should be used to determine the grade severity.  
Table  4: Criteria for Determining the Grade/Severity of Adverse Event Terms Not Specified by 
[CONTACT_790892]  
1 Mild; asymptomatic or mild symptoms, clinical or diagnostic observations only; intervention not indicated  
2 Moderate; minimal, local, or noninvasive intervention indicated; limiting age -appropriate instrumental activities of 
daily livinga 
3 Severe or medically significant but not immediately life -threatening; hospi[INVESTIGATOR_48622]; disabling; limiting self -care activities of daily livingb 
4 Life-threatening consequences; urgent intervention indicated  
5 Death related to adverse event  
a.  Instrumental activities of daily living refer to preparing meals, shoppi[INVESTIGATOR_3112], using the telephone, man aging 
money, etc.  
b.  Self-care activities of daily living refer to bathing, dressing and undressing, feeding self, using the toilet, taking medications , and 
not bedridden.  
CTCAE  = Common Terminology Criteria for Adverse Events.  

DMVT -505 (tapi[INVESTIGATOR_191752])  IND 104601  
Dermavant Sciences , Inc.  Clinical Study  Protocol  
Confidential  Page | 43 Assessment of Causality  
• The Investigator  is obligated to assess the relationship between study product  and each occurrence 
of each AE/SAE .  The Investigator  will use clinical judgment to determine the relationship.  
• A reasonable possibility of a relationship conveys that there are facts, evidence, and/or arguments 
to suggest a causal relationship, rather than a relationship cannot be ruled out.  
• Alternative causes, such as underlying disease(s), concomitant therapy, and other risk factors, as 
well as the temporal relationship of the event to study product  administration, will be considered 
and investigated.  
• For causality assessment, the Investigator  will also consult the IB and/or product information, for 
marketed products.  
• The Investigator  must review and provide an assessment of cau sality for each AE/SAE and 
document this in the medical notes .  There may be situations in which an SAE has occurred,  and 
the Investigator  has minimal information to include in the initial report to the Sponsor  or designee .  
However, it is very important t hat the Investigator  always make s an assessment of causality for 
every event before the initial transmission of the SAE data to the Sponsor  or designee . 
• The Investigator  may change their opi[INVESTIGATOR_9242] -up information and send 
an SA E follow -up report with the updated causality assessment.  
• The causality assessment is one of the criteria used when determining regulatory reporting 
requirements.  
Follow -up of AEs and SAEs  
• The Investigator  is obligated to perform or arrange for the conduct  of supplemental measurements 
and/or evaluations as medically indicated or as requested by [CONTACT_790893]/or causality of the AE or SAE as fully as possible .  This may include additional 
laboratory tests or investigatio ns, histopathological examinations, or consultation with other health 
care professionals.  
• If a participant dies during participation in the study or during a recognized follow -up period, the 
Investigator  will provide  the Sponsor  with a copy of any postmort em findings including 
histopathology , if applicable . 
• New or updated information will be recorded in the originally submitted documents.  
• The Investigator  will submit any updated SAE data to the Sponsor  or designee  within 24 hours of 
receipt of the informati on. 
10.3.4  Reporting of SAEs   
SAE Reporting to Sponsor via an Electronic Data Collection Tool  
• The primary mechanism for reporting an SAE to the Sponsor or designee will be the electronic  
data collection tool.  
• If the electronic system is unavailable, then the site will use the paper SAE data collection tool (see 
next section) to report the event within 24 hours.  
• The site will enter the SAE data into the electronic system as soon as it beco mes available.  
• After the study is completed at a given site, the electronic data collection tool will be taken offline 
to prevent the entry of new data or changes to existing data.  
• If a site receives a report of a new SAE from a study participant or receiv es updated data on a 
previously reported SAE after the electronic data collection tool has been taken offline, then the 
DMVT -505 (tapi[INVESTIGATOR_191752])  IND 104601  
Dermavant Sciences , Inc.  Clinical Study  Protocol  
Confidential  Page | 44 site can report this information on a paper SAE form (see next section) or to the Sponsor or 
designee  by [CONTACT_756].  
• Contacts for SAE rep orting can be found in Study Reference Manual . 
SAE Reporting to Sponsor or Designee  via Paper Data Collection Tool  
• Facsimile transmission of the SAE paper data collection tool is the preferred method to transmit 
this information to the Sponsor or designee  or the SAE coordinator.  
• Initial notification via telephone does not replace the need for the Investigator  to complete and sign 
the SAE data collection tool within the designated reporting timeframes.  
• Contacts for SAE reporting can be found in the Study Reference Manual . 
  
 
 
 
 
 
 
 
   
 
 
 

DMVT -505 (tapi[INVESTIGATOR_191752])  IND 104601  
Dermavant Sciences , Inc.  Clinical Study  Protocol  
Confidential  Page | 45 10.4 Appendix 4:  Contraceptive and Barrier Guidance   
10.4.1  Definitions   
Woman of Childbearing Potential (WOCBP)  
Women in the following categories are considered WOCBP (fertile):  
1. Following menarche  
2. From the time  of menarche until becoming postmenopausal unless permanently sterile (see below)  
• A postmenopausal state is defined as no menses for [ADDRESS_1090086] discontinue HRT to allow confirmation of 
postmenopausal status before study enrollment.  
• Permanent sterili zation methods (for the purpose of this study) include:  
o Documented hysterectomy  
o Documented bilateral salpi[INVESTIGATOR_1656]  
o Documented bilateral oophorectomy  
o For individuals with permanent infertility due to an alternate medical cause other than the 
above ( e.g., Mullerian agenesis, androgen insensitivity, gonadal dysgenesis), Investigator  
discretion should be applied to determining study entry.  
Note:   Documentation can come from the site personnel’s review of the participant’s medical 
records, medical examinatio n, or medical history interview.  
• If fertility is unclear ( e.g., amenorrhea in adolescents or athletes) and a menstrual cycle cannot be 
confirmed before first dose of study product , additional evaluation should be considered.  
Woman of Nonchildbearing Potent ial (WONCBP)  
Women in the following categories are considered WONCBP:  
1. Premenopausal female with permanent infertility due to one of the following:  
a. Documented hysterectomy  
b. Documented bilateral salpi[INVESTIGATOR_1656]  
c. Documented bilateral oophorectomy  
d. For individuals with permanent infertility due to an alternate medical cause other than the above 
(e.g., Mullerian agenesis, androgen insensitivity, gonadal dysgenesis), Investigator  discretion 
should be applied to determining study entry.  
Note:   Documentation can come fr om the site personnel’s review of the participant’s medical records, 
medical examination, or medical history interview.  
DMVT -505 (tapi[INVESTIGATOR_191752])  IND 104601  
Dermavant Sciences , Inc.  Clinical Study  Protocol  
Confidential  Page | [ADDRESS_1090087] discontinue HRT to allow 
confirmation of postmenopausal status before study enrollment.  
DMVT -505 (tapi[INVESTIGATOR_191752])  IND 104601  
Dermavant Sciences , Inc.  Clinical Study  Protocol  
Confidential  Page | 47 10.4.2  Contraception Guidance   
CONTRACEPTIVESa ALLOWED  DURING THE STUDY INCLUDE:  
Highly Effective Methodsb That Have Low User Dependency  Failure rate of <  1% per year when used consistently and 
correctly.  
• Implantable progestogen -only hormone contraception associated with inhibition of ovulationc 
• Intrauterine device (IUD)  
• Intrauterine hormone -releasing system (IUS)c  
• Bilateral tubal occlusion  
• Azoospermic partner (vasectomized or due to a medical cause)  
Azoospermia is a highly effective contraceptive method provided that the partner is the sole se xual partner of the WOCBP  and 
the absence of sperm has been confirmed .  If not, an additional highly effective method of contraception should be used .  
Spermatogenesis cycle is approximately 90 days.  
Note:  Documentation of azoospermia for a male participa nt can come from the site personnel’s review of the participant’s 
medical records, medical examination, or medical history interview.  
Highly Effective Methodsb That Are User Dependent  Failure rate of <  1% per year when used consistently and correctly.  
Combined (estrogen - and progestogen -containing) hormonal contraception associated with inhibition of ovulationc 
• oral 
• intravaginal  
• transdermal  
• injectable  
Progestogen -only hormone contraception associated with inhibition of ovulationc 
• oral 
• injectable  
Sexual abstinence  
Sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual intercourse during the 
entire period of risk associated with the study product .  The reliability of sexual abstinence needs to be evaluated  in relation to 
the duration of the study and the preferred and usual lifestyle of the participant.  
Effective Methodsd That Are Not Considered Highly Effective  Failure rate of ≥  1% per year when used consistently and 
correctly.  
• Progestogen -only oral hormonal contraception where inhibition of ovulation is not the primary mode of action  
• Male or female condom with or without spermicide  
• Cervical cap, diaphragm, or sponge with spermicide  
• A combination of male condom with either cervical cap, diaphragm, or sponge with spermicide (double -barrier methods)c 
a) Contraceptive use by [CONTACT_790894].  
b) Failure rate of <  1% per year w hen used consistently and correctly .  Typi[INVESTIGATOR_594885].  
c.) If locally required, in accordance with Clinical Trial Facilitation Group (CTFG) guidelines, acceptable contraceptive methods  
are li mited to those which inhibit ovulation as the primary mode of action .   
d) Considered effective, but not highly effective —failure rate of ≥  1% per year .   
Note:   Periodic abstinence (calendar, symptothermal, postovulation methods), withdrawal (coitus inter ruptus), spermicides only, 
and lactational amenorrhea method (LAM) are not acceptable methods of contraception .  Male condom and female condom 
should not be used together (due to risk of failure from friction).  
DMVT -505 (tapi[INVESTIGATOR_191752])  IND 104601  
Dermavant Sciences , Inc.  Clinical Study  Protocol  
Confidential  Page | 48 10.5 Appendix 5:  Physician Global Assessment of  Target Lesion   
In this study , this PGA should be used only to assess the target plaque PSO lesion in the head and neck 
region . 
Following the Baseline visit, assessments will be made without reference to Baseline state or any other 
previous scores .   
Scoring should not be influenced by [CONTACT_191859], participant symptoms, or impact on participant’s 
quality of life .   
Score/Grade  Description  
0 Clear  No signs of psoriasis; postinflammatory hyperpi[INVESTIGATOR_22765]  
[ADDRESS_1090088] clear  No thickening; normal to pi[INVESTIGATOR_22766]; no to minimal focal scaling  
[ADDRESS_1090089] detectable to mild thickening; pi[INVESTIGATOR_22767]; predominantly fine scaling  
3 Moderate  Clearly  distinguishable to moderate thickening; dull to bright red, clearly distinguishable erythema; 
moderate scaling  
[ADDRESS_1090090] edges; bright to deep dark red coloration; severe/coarse scaling covering 
almost all or all lesions  
Source:   Langley RGB, Feldman SR, Nyirady J, van de Kerkhof P, Papavassilis C .  The 5 -point Investigator’s Global Assessment 
(IGA) Scale: A modified tool for evaluating plaque psoriasis severity in clinical trials .  J Dermatolog Treat .  2015;26(1):23 -31. 
  
DMVT -505 (tapi[INVESTIGATOR_191752])  IND 104601  
Dermavant Sciences , Inc.  Clinical Study  Protocol  
Confidential  Page | 51    
 
 
  
  
 
 
 
 
 
 
  
  
  
 
 
 
 
 
 
  
  
  
 
 
 
 
 
 
  
 
 
    
 
  
  
 
 
 
 
 
 
  
 
 
    
 
  
     
 
 
 
 
 
 
  
 
 
    
 
  
  
 
 
 
 
 
 
  
 
 
    
 
  
  
 
 
  
    
 
 
  
 
  
 
 
  
 
  
    
 
 
 
 
 
  
 
 
    
 
  
   
 
 
 
 
 
 
  
 
 
    
 
 
  
 
 
 
 
 
  
 
 
    
 

DMVT -505 (tapi[INVESTIGATOR_191752])  IND 104601  
Dermavant Sciences , Inc.  Clinical Study  Protocol  
Confidential  Page | 52    
 
 
 
   
   
      
  
  
      
   
      
   
      
   
      
  
 
      
  
      
  
      
   
      
   
      
   
      
   
      

DMVT -505 (tapi[INVESTIGATOR_191752])  IND 104601  
Dermavant Sciences , Inc.  Clinical Study  Protocol  
Confidential  Page | 53  
 
   
 
 
   
   
   
   
      
  
      
    
      
 
   
  
      
   
      
  
      
  
